Bayer (BAYN) Price & Analysis

Compare

777 Followers

BAYN Stock Chart & Stats

Day’s Range― - ―

52-Week Range€18.38 - €31.03

Previous CloseN/A

Volume533.42K

Average Volume (3M)2.46M

Market Cap

€27.02B

Enterprise Value€59.09B

Total Cash (Recent Filing)€5.50B

Total Debt (Recent Filing)€38.43B

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Nov 11, 2025

EPS Estimate

0.38

Last Dividend Ex-Date

Apr 28, 2025

Dividend Yield0.4%

Share Statistics

EPS (TTM)1.23

Shares Outstanding982,424,100

10 Day Avg. Volume2,136,879

30 Day Avg. Volume2,464,326

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€27.60

Price Target Upside2.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Cash Flow MeasuresThe company has implemented measures to maximize cash flow generation, which is crucial given the high level of debt.

Debt ReductionNet debt at €32.6bn (FY-23: 34.5bn), which is good news.

Bears Say

Agrochemicals PerformanceBayer underperformed significantly due to weaker-than-expected agrochemicals performance and questions on long-term pharma growth.

EBITDA DeclineQ4 clean EBITDA came in at EUR 2.35bn, which is materially down y/y (-22% y/y, Stifel: €2.24bn, consensus: €2.1bn).

Generics ImpactThe Crop Science business is facing a broader-than-expected generics impact, affecting the company's overall performance.

Litigation UncertaintyOngoing litigation related to glyphosate is creating uncertainty for investors, with 67,000 cases still unsettled.

Bayer News

Oppenheimer maintains bullish stance on Corteva following split reports

Oppenheimer maintains the firm’s bullish stance on Corteva (CTVA) following media reports Friday of a potential Seed/CP split....

3d ago

CTVA

Morgan Stanley says Corteva may want to get out in front of ag landscape changes

After The Wall Street Journal reported that Corteva (CTVA) was considering separating its seed and crop chemicals businesses,...

3d ago

CTVA

Bayer announces new drug application for gadoquatrane accepted for review by FDA

Bayer (BAYRY) announced that a new drug application for its investigational contrast agent gadoquatrane has been accepted for...

22d ago

Bayer AG’s New Pediatric Study: A Closer Look at Rivaroxaban for VTE

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Study Overview: Bayer...

27d ago

Bayer AG’s Promising Phase 3 Study on Prostate Cancer Treatment

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Study Overview: Bayer...

27d ago

Bayer’s New Clinical Study on HER2-Targeted Cancer Treatment: A Potential Game Changer

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Bayer AG has...

27d ago

Bayer AG’s Exploratory Study on Sepsis and DIC: A Potential Game Changer?

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Bayer AG is...

27d ago

Bayer AG’s Innovative Phase I Study: A New Frontier in Cancer Treatment

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Study Overview: Bayer...

27d ago

Bayer’s Observational Study on Darolutamide: A Potential Game-Changer for Prostate Cancer Treatment

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Bayer AG is...

27d ago

Bayer’s Darolutamide Safety Study in Korea: Key Insights for Investors

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Bayer AG has...

27d ago

Bayer’s Pediatric Study on Rivaroxaban: A Potential Game-Changer for VTE Treatment

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Study Overview: Bayer...

29d ago

Bayer’s New Study on Darolutamide: A Potential Game-Changer in Prostate Cancer Treatment

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Bayer AG has...

29d ago

Bayer’s Phase 2 Study on BAY2927088: A Potential Game-Changer in HER2-Positive Tumor Treatment

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Study Overview: Bayer...

29d ago

Bayer sees FY25 sales EUR 46B-EUR 48B on currency-adjusted basis

On July 31, Bayer (BAYRY) said, “Due to a better-than-expected business performance at Pharmaceuticals in the first half...

1M ago

BAYN FAQ

What was Bayer’s price range in the past 12 months?

Bayer lowest stock price was €18.38 and its highest was €31.03 in the past 12 months.

What is Bayer’s market cap?

Bayer’s market cap is €27.02B.

When is Bayer’s upcoming earnings report date?

Bayer’s upcoming earnings report date is Nov 11, 2025 which is in 54 days.

How were Bayer’s earnings last quarter?

Bayer released its earnings results on Aug 06, 2025. The company reported €1.23 earnings per share for the quarter, beating the consensus estimate of €0.898 by €0.332.

Is Bayer overvalued?

According to Wall Street analysts Bayer’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bayer pay dividends?

Bayer pays a Annually dividend of €0.11 which represents an annual dividend yield of 0.4%. See more information on Bayer dividends here

What is Bayer’s EPS estimate?

Bayer’s EPS estimate is 0.38.

How many shares outstanding does Bayer have?

Bayer has 982,424,100 shares outstanding.

What happened to Bayer’s price movement after its last earnings report?

Bayer reported an EPS of €1.23 in its last earnings report, beating expectations of €0.898. Following the earnings report the stock price went down -9.919%.

Which hedge fund is a major shareholder of Bayer?

Currently, no hedge funds are holding shares in DE:BAYN

Bayer Stock Smart Score

Neutral

Fundamentals

Return on Equity

-10.35%

Trailing 12-Months

Asset Growth

-12.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bayer

Bayer AG is a global life sciences company headquartered in Leverkusen, Germany, operating primarily in the sectors of pharmaceuticals, consumer health, and crop science. The company is dedicated to advancing health and nutrition through innovative products and solutions, including prescription medications, over-the-counter healthcare products, and agricultural solutions such as seeds and crop protection. Bayer's commitment to research and development drives its extensive portfolio, addressing critical health and agricultural challenges worldwide.

Bayer (BAYN) Earnings & Revenues

Historic Earnings Reports

BAYN Stock 12 Month Forecast

Average Price Target

€27.60

▲(2.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"€18","27":"€27","36":"€36","22.5":"€22.5","31.5":"€31.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€27.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,22.5,27,31.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.86,28.409230769230767,28.95846153846154,29.507692307692306,30.056923076923077,30.606153846153845,31.155384615384616,31.704615384615384,32.253846153846155,32.80307692307692,33.35230769230769,33.901538461538465,34.45076923076923,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.86,27.84,27.82,27.8,27.78,27.76,27.740000000000002,27.72,27.7,27.68,27.66,27.64,27.62,{"y":27.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.86,27.486153846153847,27.11230769230769,26.73846153846154,26.364615384615384,25.99076923076923,25.616923076923076,25.243076923076924,24.869230769230768,24.495384615384616,24.12153846153846,23.747692307692308,23.373846153846152,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.895,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.299,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.979,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.193,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.221,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.536,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.601,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.208,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >